Clinical Trials Directory

Trials / Not Yet Recruiting

Not Yet RecruitingNCT06506175

Investigation of Optimal Dosage Regimen for HRS9531 Tablets in Healthy Subjects

A Phase I Clinical Trial to Evaluate the Effects of Different Dosing Conditions, Timing and Food on the Pharmacokinetics of HRS9531 Tablets in Healthy Subjects

Status
Not Yet Recruiting
Phase
Phase 1
Study type
Interventional
Enrollment
144 (estimated)
Sponsor
Fujian Shengdi Pharmaceutical Co., Ltd. · Industry
Sex
Male
Age
18 Years – 55 Years
Healthy volunteers
Accepted

Summary

The study is being conducted to evaluate the effects of different dosage regimen on the pharmacokinetics of HRS9531 tablets in healthy subjects.

Conditions

Interventions

TypeNameDescription
DRUGHRS9531 tabletsHRS9531 tablets

Timeline

Start date
2024-08-05
Primary completion
2024-11-30
Completion
2024-11-30
First posted
2024-07-17
Last updated
2024-07-17

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT06506175. Inclusion in this directory is not an endorsement.

Investigation of Optimal Dosage Regimen for HRS9531 Tablets in Healthy Subjects (NCT06506175) · Clinical Trials Directory